📊 IMUX Key Takeaways
Is Immunic, Inc.. (IMUX) a Good Investment?
IMMUNIC is a pre-commercial biotech company with virtually no revenue ($22K) and massive operating losses ($33.2M annually), resulting in catastrophic profitability metrics. While the balance sheet is fortress-strong with $186.6M cash and zero debt, the company is burning $17.3M in operating cash annually with no clear near-term path to profitability. The financial fundamentals indicate a speculative pre-revenue stage company dependent entirely on pipeline success and future commercialization.
Immunic shows extreme operating losses, negative equity, and sub-1.0 liquidity with negligible revenue, indicating acute financial stress and going‑concern risk. Cash of ~$15.5M against roughly ~$85.8M annual operating cash burn implies a very short runway and likely need for immediate external financing. Without credible revenue traction or cost containment, fundamentals remain deteriorated.
Why Buy Immunic, Inc.. Stock? IMUX Key Strengths
- Fortress balance sheet with $186.6M cash equivalents providing 10+ years of runway at current burn rate
- Zero debt and low liabilities ($38.5M), resulting in clean capital structure
- Excellent liquidity with 4.92x current ratio, eliminating near-term solvency concerns
- Asset-light model with minimal capex needs
- YoY improvement in EPS and net loss (still negative)
- Cash balance provides limited near-term flexibility
IMUX Stock Risks: Immunic, Inc.. Investment Risks
- Pre-commercial revenue model with only $22K in revenue and no profitability trajectory visible
- Annual cash burn of $17.3M depleting equity capital despite strong starting position
- Massive negative profitability ratios (operating margin -151068%, net margin -148127%) indicating fundamental business model failure at current stage
- Complete dependence on successful clinical development and commercialization of pipeline products for survival
- Liquidity/solvency risk from sub-1.0 current ratio and negative equity
- Severe cash burn and negative FCF likely forcing dilutive financing
- Sustained lack of revenue scale and negative interest coverage
Key Metrics to Watch
- Revenue growth trajectory and timing of commercial product launches
- Quarterly cash burn rate and updated cash runway estimates
- Clinical trial progress, regulatory approvals, and pipeline advancement milestones
- Quarterly operating cash flow (burn rate)
- Cash & equivalents and current ratio
Immunic, Inc.. (IMUX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.92x current ratio provides a solid financial cushion.
IMUX Profit Margin, ROE & Profitability Analysis
IMUX vs Healthcare Sector: How Immunic, Inc.. Compares
How Immunic, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Immunic, Inc.. Stock Overvalued? IMUX Valuation Analysis 2026
Based on fundamental analysis, Immunic, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Immunic, Inc.. Balance Sheet: IMUX Debt, Cash & Liquidity
IMUX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Immunic, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.00 indicates the company is currently unprofitable.
IMUX Revenue Growth, EPS Growth & YoY Performance
IMUX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2014 | $22.0K | -$9.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Immunic, Inc.. Dividends, Buybacks & Capital Allocation
IMUX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Immunic, Inc.. (CIK: 0001280776)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IMUX
What is the AI rating for IMUX?
Immunic, Inc.. (IMUX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IMUX's key strengths?
Claude: Fortress balance sheet with $186.6M cash equivalents providing 10+ years of runway at current burn rate. Zero debt and low liabilities ($38.5M), resulting in clean capital structure. ChatGPT: Asset-light model with minimal capex needs. YoY improvement in EPS and net loss (still negative).
What are the risks of investing in IMUX?
Claude: Pre-commercial revenue model with only $22K in revenue and no profitability trajectory visible. Annual cash burn of $17.3M depleting equity capital despite strong starting position. ChatGPT: Liquidity/solvency risk from sub-1.0 current ratio and negative equity. Severe cash burn and negative FCF likely forcing dilutive financing.
What is IMUX's revenue and growth?
Immunic, Inc.. reported revenue of $22.0K.
Does IMUX pay dividends?
Immunic, Inc.. does not currently pay dividends.
Where can I find IMUX SEC filings?
Official SEC filings for Immunic, Inc.. (CIK: 0001280776) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IMUX's EPS?
Immunic, Inc.. has a diluted EPS of $-1.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IMUX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Immunic, Inc.. has a SELL rating with 79% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IMUX stock overvalued or undervalued?
Valuation metrics for IMUX: ROE of -21.5% (sector avg: 15%), net margin of -148,127.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IMUX stock in 2026?
Our dual AI analysis gives Immunic, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IMUX's free cash flow?
Immunic, Inc..'s operating cash flow is $-17.3M, with capital expenditures of $2.0K. FCF margin is -78,650.0%.
How does IMUX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -148,127.3% (avg: 12%), ROE -21.5% (avg: 15%), current ratio 4.92 (avg: 2).